Takeda’s zasocitinib data sets up PsO filing

Japanese drugmaker Takeda (TYO: 4502) has announced positive topline results for two pivotal Phase III studies of zasocitinib (TAK-279), a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).

Once-daily oral zasocitinib met all primary and ranked secondary endpoints in the trials.

More than half of the study participants in the treatment arm achieved clear or almost clear skin (PASI 90), and on average about 30% achieved completely clear skin (PASI 100) by week 16, with zasocitinib generally well-tolerated with a safety profile consistent with previous clinical studies.